Ideally, anti-cancer treatments should specifically target and kill tumour cells while leaving normal, healthy tissues relatively unscathed. The therapeutic ratio of the maximum tolerated to the ...
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate ...
AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, based on proprietary GlycoConnect™, HydraSpace™ and ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...
ADC Design The fundamental components of an ADC are a mAb directed against a tumor-associated antigen, a cytotoxic agent called payload, and a connecting linker. Each component and their interactions ...
Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...
Antibody-drug conjugates (ADCs), also known as armed antibodies, are positioned to be a significant source of next-generation oncolytic therapies. There has been explosive growth in ADC R&D, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results